Medicare Urged To Allow Home Infusion Plan With Direct Buying, Billing By Outside Providers
Manufacturers seek additional flexibility from Medicare to facilitate home infusions as surveys indicate patient visits to physician offices have dropped by 40% to 68% in recent weeks, signaling a decline in adherence for physician-administered drugs.
You may also be interested in...
Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.
Plan to allow broader coverage for home infused drugs during the COVID-19 emergency prompts opposition from providers seeking an approach more in line with commercial insurance practices.
Bipartisan congressional letters seek relief from HHS but the Trump Administration has taken aim at 340B providers itself and may not be inclined to help.